Our founding program, cTAP-Duchenne convenes a global coalition of some of the most prominent stakeholders in the Duchenne community. It is an international group of academic researchers, clinical registries from leading research institutions in Duchenne muscular dystrophy, pioneering advocacy organizations that have led the way in the fight against Duchenne, and drug developers including multinational pharmaceutical companies and smaller biotechnology firms.
Today, cTAP-Duchenne pursues a robust research agenda spanning analytical research, support to improve the sophistication and sustainability of accessible patient data resources, and workshops to advance cross-stakeholder conversation and alignment on priority research problems. Contact us to learn more and get involved.
Meet our collaborators below, and click here to read a case study of how cTAP-Duchenne began, our research agenda first took shape, and 10 years of results are adding up for patients.
Patient Groups
Biopharmaceutical Companies
Clinical Networks
Data Science
cTAP is committed to helping other rare neuromuscular diseases avoid years of futile research and unnecessary trial failures from lack of understanding of patient data. Stay tuned for announcement of our next collaborations, or better yet, get in touch about starting one.